

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2007 (03.05.2007)

PCT

(10) International Publication Number
WO 2007/048224 A1

(51) International Patent Classification:
C07D 295/16 (2006.01) *A61P 35/00* (2006.01)
A61K 31/40 (2006.01)

(74) Agent: GOWLING LAFLEUR HENDERSON LLP; 1
Place Ville Marie, 37th Floor, Montreal, Québec H3B 3P4
(CA).

(21) International Application Number:
PCT/CA2006/001721

(22) International Filing Date: 20 October 2006 (20.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/729,727 25 October 2005 (25.10.2005) US
60/830,662 14 July 2006 (14.07.2006) US

(71) Applicant (for all designated States except US): AEGERA
THERAPEUTICS INC. [CA/CA]; 810 Chemin du Golf,
Verdun, Quebec H3E 1A8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LAURENT, Alain
[FR/CA]; 5266 Chemin de la Cote St-Paul, Montreal,
Quebec H4C 1X1 (CA). HEWITT, Kim [CA/CA]; 4855
Chemin Cote St. Luc #306, Montreal, Quebec H3W
2H5 (CA). MORRIS, Stephen [CA/CA]; 147 Chartwell
Drive, Beaconsfield, Quebec H9W 1C2 (CA). BUREAU,
Patrick [CA/CA]; 93 Timberlea Trail, Kirkland, Quebec
H9J 2T3 (CA). BOUDREAULT, Alain [CA/CA]; 120
Avenue Claude, Dorval, Quebec H9S 3A7 (CA). JARVIS,
Scott [CA/CA]; 1542 Labrie, Longueuil, Quebec J4G 2J9
(CA). JAQUITH, James, B. [CA/CA]; 59 Boise du Parc,
Pincourt, Quebec J7V 9B6 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IAP BIR DOMAIN BINDING COMPOUNDS



(57) Abstract: The present disclosure relates to compounds that bind to IAP BIR domains, more particularly the BIR2 and BIR3 domains. The compounds are represented by Formula 1 : (I) These compounds have been found to be useful in altering apoptotic responses in cells which can lead to the treatment of proliferative disorders. Apoptotic pathways are known to play a critical role in the development of cancer, autoimmune disorders and neurodegenerative diseases. A process to make the compounds of Formula 1 is also disclosed.

WO 2007/048224 A1